Your browser is no longer supported. Please, upgrade your browser.
SNY Sanofi daily Stock Chart
Index- P/E29.76 EPS (ttm)1.80 Insider Own- Shs Outstand2.65B Perf Week0.37%
Market Cap142.09B Forward P/E16.74 EPS next Y3.20 Insider Trans- Shs Float2.38B Perf Month8.16%
Income4.75B PEG3.67 EPS next Q- Inst Own9.90% Short Float0.13% Perf Quarter9.51%
Sales38.52B P/S3.69 EPS this Y19.00% Inst Trans0.28% Short Ratio1.86 Perf Half Y17.78%
Book/sh23.67 P/B2.26 EPS next Y1.43% ROA4.50% Target Price56.60 Perf Year6.09%
Cash/sh3.15 P/C17.03 EPS next 5Y8.10% ROE7.80% 52W Range42.16 - 55.57 Perf YTD21.37%
Dividend1.61 P/FCF- EPS past 5Y-3.90% ROI7.00% 52W High-3.59% Beta1.10
Dividend %3.01% Quick Ratio1.30 Sales past 5Y1.80% Gross Margin67.80% 52W Low27.05% ATR0.96
Employees113496 Current Ratio1.80 Sales Q/Q12.20% Oper. Margin19.60% RSI (14)60.10 Volatility1.82% 1.38%
OptionableYes Debt/Eq0.26 EPS Q/Q-4.40% Profit Margin12.40% Rel Volume0.50 Prev Close52.64
ShortableYes LT Debt/Eq0.24 EarningsJul 30 BMO Payout47.60% Avg Volume1.67M Price53.57
Recom1.70 SMA203.47% SMA505.32% SMA20011.66% Volume836,797 Change1.77%
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Sep-23-08Downgrade Credit Suisse Neutral → Underperform
Oct-24-07Initiated Bernstein Mkt Perform
Sep-06-07Initiated UBS Neutral
Jul-18-07Upgrade HSBC Securities Neutral → Overweight
Jun-14-07Reiterated Banc of America Sec Buy $50 → $48
Jul-30-15 06:10PM  Sanofi (SNY) Earnings Report: Q2 2015 Conference Call Transcript at TheStreet
04:18PM  Amgen beats big on bottom line
03:40PM  Sales of MannKind's inhaled insulin continue slow start at Los Angeles Times
03:00PM  How many multiple sclerosis patients are in the U.S.? No one knows. at
12:44PM  Why MannKind Corp. Stock Briefly Dropped Today at Motley Fool
12:13PM  10 Stocks Making Warren Buffett Richer in 2015 at TheStreet
11:52AM  MannKind slumps after Sanofi details Afrezza sales
11:03AM  MannKind Afrezza Sales Underwhelming Again, Sanofi Reports at TheStreet
07:40AM  Sanofi calls out Genzyme, multiple sclerosis drug, as main drivers of growth again at
07:30AM  A Health Care ETF Making new Highs
07:30AM  Sanofi Delivers Solid Sales and Business EPS Growth in Q2 2015 PR Newswire
06:39AM  Strong dollar helps push Sanofi profit higher in second quarter at Financial Times
04:54AM  Sanofi's diabetes sales slow, Genzyme's jump
03:56AM  Sanofi Buoyed by Biotech and Lower Costs at The Wall Street Journal
02:45AM  Sanofi H1 2015 Results - Interview with CEO Olivier Brandicourt PR Newswire
02:36AM  Sanofi's diabetes division sales slow in Q2, Genzyme jumps
01:35AM  Sanofi Profit Beats Estimates on Multiple Sclerosis Drugs at Bloomberg
01:30AM  Sanofi Profit Beats Estimates as Multiple Sclerosis Drugs Gain at Bloomberg
12:33AM  Sanofi delivers solid sales and business EPS(1) growth in Q2 2015 ACN Newswire
Jul-29-15 03:45PM  Sanofi & Regeneron Enter Immuno-Oncology Collaboration - Analyst Blog
11:27AM  Sanofi-Regeneron: Third Time's the Charm? at
08:00AM  Genzyme Launches Fifth Annual Patient Advocacy Leadership (PAL) Awards Program Business Wire
07:00AM  Sanofi Announces that First LixiLan Phase III Study Met Primary Endpoint PR Newswire
Jul-28-15 08:07PM  5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen at Investor's Business Daily
05:32PM  Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal at Investor's Business Daily
03:52PM  Eurozone Business Activity Seems Undeterred by Greek Crisis
01:57PM  Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?
11:08AM  Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief at Forbes
10:23AM  Struggling Sanofi Sends Cancer SOS to Regeneron and Another Vanity Biotech IPO Launches at TheStreet
02:42AM  Sanofi links with Regeneron in $2.2 bln cancer drug push
01:00AM  Sanofi Joins Regeneron in $2.2 Billion Pact for Cancer Therapies at Bloomberg
01:00AM  Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration PR Newswire
Jul-27-15 02:56PM  Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval at Motley Fool
01:55PM  Sanofi paying up to $300M for rare thyroid cancer drug
12:43PM  Why Regeneron's Approval is Bad News For Esperion Therapeutics at
11:53AM  Have Analysts Fully Priced in Praluent to Regeneron?
10:00AM  AZN sells off non-core drugs
02:00AM  Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa® (vandetanib) from AstraZeneca Business Wire
Jul-24-15 05:24PM  Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK at Investor's Business Daily
05:24PM  Regeneron Cholesterol Fighter Wins FDA OK, With Conditions
03:53PM  Sanofi and Regeneron Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients PR Newswire
03:17PM  Regeneron and Sanofi Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients PR Newswire
02:43PM  Sanofi Cholesterol Drug Approved in U.S. for Some Patients at Bloomberg
07:15AM  Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia PR Newswire
Jul-23-15 01:04PM  The Future Of MannKind at Insider Monkey
Jul-22-15 04:25PM  Amgen's Repatha Gains EU Nod; First PCSK9 Drug Approved - Analyst Blog
03:59PM  Actelion Misses on Q2 Earnings, Revenues Beat Expectations - Analyst Blog
12:45PM  Abbott Laboratories (ABT) Beats on Q2 Earnings, Keeps View - Analyst Blog
03:37AM  Amgen and Sanofi to battle for cholesterol-busting crown at Financial Times
Jul-20-15 12:30PM  Why Genzyme isn't worried about a threat by Amicus to its next Fabry drug at
04:56AM  Sanofi confident dengue drug will benefit patients and investors at Financial Times
Jul-16-15 03:35PM  Sanofi Unveils Restructuring Plans, Prunes Business Units - Analyst Blog
01:45PM  Genzymes expansion is good news for Massachusetts, but comes with a price at
Jul-15-15 03:15PM  Cytokinetics Advances Tirasemtiv to Phase III, Shares Up - Analyst Blog
09:04AM  Sanofi trims number of divisions from seven to five
Jul-14-15 04:50PM  Anacor Hits 52-Week High on Positive Atopic Dermatitis Data - Analyst Blog
08:00AM  Sanofi Pasteur Ships First 2015-2016 Seasonal Influenza Vaccine Doses in United States PR Newswire
Jul-13-15 05:58AM  Campaign Launched to Raise Awareness of Risks of Familial Hypercholesterolaemia (FH) PR Newswire
Jul-10-15 09:28AM  Merial Introduces Oravet® Dental Hygiene Chews for Dogs PR Newswire +5.56%
Jul-09-15 02:00PM  [$$] Regeneron 'Sell' Rating Is Right Call for This Biotech at
01:20PM  Google locks up more space in 'essentially 100% leased' Kendall Center at
11:30AM  Regeneron and Sanofi Report Positive Data on Praluent - Analyst Blog
11:04AM  FDA Should Withdraw Sanofi Device Over Safety Concerns: Advocacy Group at The Wall Street Journal
08:49AM  Looking for a Top Value Stock? 3 Reasons Why Sanofi (SNY) is an Excellent Choice - Tale of the Tape
08:07AM  The Reason MannKind Stock Galloped 10% Higher in June at Motley Fool
Jul-08-15 10:00PM  Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection PR Newswire
11:00AM  3 Great European Stocks for Dividend Investors at Kiplinger
Jul-07-15 04:40PM  Isis Pharmaceuticals' Lipid Disorder Drug Gets Orphan Status - Analyst Blog
09:14AM  Watchdog urges FDA to revoke approval of Genzyme surgical implant Reuters
Jul-02-15 08:51AM  Never mind Greece, Europe will beat the U.S.: Strategist
Jul-01-15 04:12PM  What Is Beyond Vision-Loss Blockbuster For Regeneron? at Investor's Business Daily
03:46PM  Analysts Battle Over MannKind -- but Who's Right? at Investopedia
09:30AM  The Zacks Analyst Blog Highlights: Delhaize Group, Sanofi and Luxfer Holdings - Press Releases
Jun-30-15 11:27AM  MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin at TheStreet
10:42AM  Roche 'High Efficacy' MS Drug Succeeds In Trials at Investor's Business Daily
10:19AM  Is Grexit Inevitable? 3 Stocks to Buy - Analyst Blog
08:00AM  New Film Documents Heart Felt Stories of People Living with High LDL Cholesterol PR Newswire
Jun-26-15 04:03AM  New Sanofi CEO to unveil five-year plan in November -unions Reuters
Jun-24-15 01:33PM  Eurozone Business Activity Is at Its Highest Level in 4 Years
09:30AM  Pep Boys, Acacia Research, Sanofi, Unilever and Continental Aktiengesellschaft highlighted as Zacks Bull and Bear of the Day - Press Releases
Jun-23-15 12:31PM  Viehbacher to head $2bn Bertarelli healthcare fund at Financial Times
10:30AM  Greece Deal Likely? 3 Stock Picks - Analyst Blog
03:00AM  Former Sanofi CEO Makes Science Comeback With Bertarelli Fund at Bloomberg
Jun-22-15 03:17PM  Top Europe Stocks Rally On Greece Bailout Hopes at Investor's Business Daily
Jun-19-15 01:41PM  Biotechs about to break out: Pro
Jun-16-15 04:50PM  Sanofi Starts Dosing in Phase I/II Study on Olipudase Alfa - Analyst Blog
12:39PM  We've Only Seen This Contrarian Buy Signal One Other Time Since 2009 at Forbes
Jun-15-15 04:30PM  Alnylam Reveals Positive Initial Data on RNAi Drug ALN-CC5 - Analyst Blog
11:06AM  Bad News from Greece as It Postpones Grexit, but GREK Is Up 1.08%
10:16AM  Regeneron: Don't Worry, Be Happy at
08:00AM  Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients Business Wire
Jun-12-15 09:00AM  Steven Nissen, Conflicts Of Interest, And The New Cholesterol Drugs at Forbes
Jun-11-15 01:00PM  Johns Hopkins gets seat at table for grantmaking by French drugmaker Sanofi at
10:10AM  S&P downgrades Greece ratings: Pro
08:59AM  Krispy Kreme pops; Lululemon founder sells stake; Nike inks NBA deal
08:10AM  Retail sales rebound; Nike's big NBA score; LA minimum wage hike
Jun-10-15 05:35PM  Amgen Cholesterol Drug Repatha Wins FDA Panel Vote at Investor's Business Daily
04:40PM  Regeneron/Sanofi's Praluent Gets Positive FDA Panel Vote - Analyst Blog
04:30PM  MannKind Corporation Sinks: CFO Says 'We're Not There Yet' With Afrezza
04:27PM  French biotech giant banks on innovation with area hospitals at
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJul 27Buy537.4810,6395,718,27222,869,783Jul 29 05:46 PM
Sanofi10% OwnerDec 24Buy398.7930,00211,964,50122,859,144Dec 29 05:40 PM
Sanofi10% OwnerDec 23Buy392.23171,45767,251,14222,829,142Dec 29 05:40 PM
Sanofi10% OwnerOct 16Buy335.35122,12740,955,05722,657,685Oct 20 05:45 PM
Sanofi10% OwnerOct 15Buy328.16158,36851,970,26522,535,558Oct 17 05:05 PM